Loading...

PE/Cyanine7 anti-mouse CD69 Antibody PE/Cyanine7 anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_PECy7_091907
Con A-stimulated Balb/c mouse splenocytes (24 hours) stained with H1.2F3 PE/Cyanine7
  • H1dot2F3_PECy7_091907
    Con A-stimulated Balb/c mouse splenocytes (24 hours) stained with H1.2F3 PE/Cyanine7
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
104511 25 µg DKK458
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104512 100 µg DKK1129
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  2. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  3. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  4. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  5. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  6. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  7. du Halgouet A, et al. 2023. Immunity. 56:78. PubMed
  8. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  9. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  10. Fiege JK, et al. 2021. Cell Host Microbe. 29:1815. PubMed
  11. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  12. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  13. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  14. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  15. Israelow B, et al. 2020. bioRxiv. . PubMed
  16. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  17. Redmann V, et al. 2016. Sci Rep. 6:23326. PubMed
  18. Muris A, et al. 2012. J Immunol Methods. 381:59. PubMed
  19. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  20. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  21. Wang D, et al. 2018. Immunity. 48:659. PubMed
  22. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  23. Muthuswamy R, et al. 2021. J Immunother Cancer. 9:. PubMed
  24. Cannons JL, et al. 2021. Cell Rep. 37:109804. PubMed
  25. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  26. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  27. Uhlig K, et al. 2015. J Virol. 89: 9044-9060. PubMed
  28. Israelow B, et al. 2021. Sci Immunol. 6:eabl4509. PubMed
  29. McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed
  30. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  31. Chung H, et al. 2021. Immune Netw. 21:e28. PubMed
  32. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  33. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  34. Silva M, et al. 2021. Sci Immunol. 6:eabf1152. PubMed
  35. Müller M, et al. 2021. Nat Commun. 12:7036. PubMed
  36. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  37. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  38. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  39. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
  40. Nelson SA, et al. 2022. NPJ Vaccines. 7:124. PubMed
  41. Levescot A, et al. 2021. J Clin Invest. 131:. PubMed
  42. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  43. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  44. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  45. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  46. Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed
  47. Nayak RR, et al. 2021. Cell Host Microbe. 29(3):362-377.e11. PubMed
  48. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  49. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
  50. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  51. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  52. Van Braeckel-Budimir N, et al. 2018. Cell Rep. 24:3374. PubMed
  53. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  54. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  55. Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed
  56. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  57. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  58. Mendelsohn AC, et al. 2020. Am J Physiol Cell Physiol. 319:C997. PubMed
  59. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  60. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  61. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  62. Tsalavos S, et al. 2011. J Immunol. 186:6860. PubMed
  63. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  64. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  65. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  66. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  67. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  68. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  69. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  70. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  71. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  72. Qi H, et al. 2020. Cell Reports. 31(6):107621. PubMed
  73. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
  74. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  75. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  76. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  77. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  78. Pan Y, et al. 2021. NPJ Vaccines. 6:1. PubMed
  79. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  80. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  81. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  82. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  83. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  84. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  85. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  86. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  87. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  88. du Halgouet A, et al. 2023. Immunity. 56:78. PubMed
  89. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  90. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  91. Fiege JK, et al. 2021. Cell Host Microbe. 29:1815. PubMed
  92. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  93. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  94. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  95. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  96. Israelow B, et al. 2020. bioRxiv. . PubMed
  97. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  98. Redmann V, et al. 2016. Sci Rep. 6:23326. PubMed
  99. Muris A, et al. 2012. J Immunol Methods. 381:59. PubMed
  100. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  101. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  102. Wang D, et al. 2018. Immunity. 48:659. PubMed
  103. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  104. Muthuswamy R, et al. 2021. J Immunother Cancer. 9:. PubMed
  105. Cannons JL, et al. 2021. Cell Rep. 37:109804. PubMed
  106. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  107. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  108. Uhlig K, et al. 2015. J Virol. 89: 9044-9060. PubMed
  109. Israelow B, et al. 2021. Sci Immunol. 6:eabl4509. PubMed
  110. McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed
  111. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  112. Chung H, et al. 2021. Immune Netw. 21:e28. PubMed
  113. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  114. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  115. Silva M, et al. 2021. Sci Immunol. 6:eabf1152. PubMed
  116. Müller M, et al. 2021. Nat Commun. 12:7036. PubMed
  117. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  118. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  119. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  120. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
  121. Nelson SA, et al. 2022. NPJ Vaccines. 7:124. PubMed
  122. Levescot A, et al. 2021. J Clin Invest. 131:. PubMed
  123. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  124. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  125. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  126. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  127. Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed
  128. Nayak RR, et al. 2021. Cell Host Microbe. 29(3):362-377.e11. PubMed
  129. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  130. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
  131. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  132. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  133. Van Braeckel-Budimir N, et al. 2018. Cell Rep. 24:3374. PubMed
  134. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  135. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  136. Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed
  137. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  138. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  139. Mendelsohn AC, et al. 2020. Am J Physiol Cell Physiol. 319:C997. PubMed
  140. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  141. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  142. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  143. Tsalavos S, et al. 2011. J Immunol. 186:6860. PubMed
  144. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  145. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  146. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  147. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  148. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  149. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  150. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  151. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  152. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  153. Qi H, et al. 2020. Cell Reports. 31(6):107621. PubMed
  154. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
  155. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  156. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  157. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  158. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  159. Pan Y, et al. 2021. NPJ Vaccines. 6:1. PubMed
  160. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  161. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  162. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
RRID
AB_493565 (BioLegend Cat. No. 104511)
AB_493564 (BioLegend Cat. No. 104512)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse CD69 (Maxpar® Ready) H1.2F3 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 711™ anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 700 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 650™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 785™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-A0197 anti-mouse CD69 H1.2F3 PG
APC/Fire™ 750 anti-mouse CD69 H1.2F3 FC
TotalSeq™-C0197 anti-mouse CD69 H1.2F3 PG
TotalSeq™-B0197 anti-mouse CD69 H1.2F3 PG
KIRAVIA Blue 520™ anti-mouse CD69 H1.2F3 FC
Spark NIR™ 685 anti-mouse CD69 H1.2F3 FC
Biotin anti-mouse CD69 H1.2F3 FC
FITC anti-mouse CD69 H1.2F3 FC
PE anti-mouse CD69 H1.2F3 FC
PE/Cyanine5 anti-mouse CD69 H1.2F3 FC
Purified anti-mouse CD69 H1.2F3 FC,IHC-F,IP
PE/Cyanine7 anti-mouse CD69 H1.2F3 FC
APC anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 488 anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 647 anti-mouse CD69 H1.2F3 FC
PerCP/Cyanine5.5 anti-mouse CD69 H1.2F3 FC
PerCP anti-mouse CD69 H1.2F3 FC
Pacific Blue™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 421™ anti-mouse CD69 H1.2F3 FC
APC/Cyanine7 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 605™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 510™ anti-mouse CD69 H1.2F3 FC
Spark Red™ 718 anti-mouse CD69 H1.2F3 FC
Spark Blue™ 574 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark PLUS B550™ anti-mouse CD69 H1.2F3 FC
Spark PLUS UV395™ anti-mouse CD69 Antibody H1.2F3 FC
Spark YG™ 581 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark YG™ 593 anti-mouse CD69 (Flexi-Fluor™) Antibody H1.2F3 FC
Spark UV™ 387 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Go To Top Version: 3    Revision Date: 04/18/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_PECy7_091907
Con A-stimulated Balb/c mouse splenocytes (24 hours) stained with H1.2F3 PE/Cyanine7
  • H1dot2F3_PECy7_091907
    Con A-stimulated Balb/c mouse splenocytes (24 hours) stained with H1.2F3 PE/Cyanine7
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
104511 25 µg DKK458
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104512 100 µg DKK1129
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  2. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  3. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  4. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  5. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  6. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  7. du Halgouet A, et al. 2023. Immunity. 56:78. PubMed
  8. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  9. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  10. Fiege JK, et al. 2021. Cell Host Microbe. 29:1815. PubMed
  11. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  12. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  13. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  14. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  15. Israelow B, et al. 2020. bioRxiv. . PubMed
  16. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  17. Redmann V, et al. 2016. Sci Rep. 6:23326. PubMed
  18. Muris A, et al. 2012. J Immunol Methods. 381:59. PubMed
  19. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  20. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  21. Wang D, et al. 2018. Immunity. 48:659. PubMed
  22. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  23. Muthuswamy R, et al. 2021. J Immunother Cancer. 9:. PubMed
  24. Cannons JL, et al. 2021. Cell Rep. 37:109804. PubMed
  25. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  26. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  27. Uhlig K, et al. 2015. J Virol. 89: 9044-9060. PubMed
  28. Israelow B, et al. 2021. Sci Immunol. 6:eabl4509. PubMed
  29. McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed
  30. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  31. Chung H, et al. 2021. Immune Netw. 21:e28. PubMed
  32. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  33. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  34. Silva M, et al. 2021. Sci Immunol. 6:eabf1152. PubMed
  35. Müller M, et al. 2021. Nat Commun. 12:7036. PubMed
  36. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  37. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  38. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  39. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
  40. Nelson SA, et al. 2022. NPJ Vaccines. 7:124. PubMed
  41. Levescot A, et al. 2021. J Clin Invest. 131:. PubMed
  42. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  43. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  44. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  45. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  46. Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed
  47. Nayak RR, et al. 2021. Cell Host Microbe. 29(3):362-377.e11. PubMed
  48. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  49. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
  50. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  51. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  52. Van Braeckel-Budimir N, et al. 2018. Cell Rep. 24:3374. PubMed
  53. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  54. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  55. Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed
  56. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  57. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  58. Mendelsohn AC, et al. 2020. Am J Physiol Cell Physiol. 319:C997. PubMed
  59. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  60. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  61. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  62. Tsalavos S, et al. 2011. J Immunol. 186:6860. PubMed
  63. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  64. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  65. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  66. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  67. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  68. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  69. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  70. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  71. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  72. Qi H, et al. 2020. Cell Reports. 31(6):107621. PubMed
  73. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
  74. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  75. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  76. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  77. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  78. Pan Y, et al. 2021. NPJ Vaccines. 6:1. PubMed
  79. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  80. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  81. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  82. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  83. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  84. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
  85. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  86. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  87. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  88. du Halgouet A, et al. 2023. Immunity. 56:78. PubMed
  89. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  90. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  91. Fiege JK, et al. 2021. Cell Host Microbe. 29:1815. PubMed
  92. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  93. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  94. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  95. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  96. Israelow B, et al. 2020. bioRxiv. . PubMed
  97. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  98. Redmann V, et al. 2016. Sci Rep. 6:23326. PubMed
  99. Muris A, et al. 2012. J Immunol Methods. 381:59. PubMed
  100. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  101. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  102. Wang D, et al. 2018. Immunity. 48:659. PubMed
  103. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  104. Muthuswamy R, et al. 2021. J Immunother Cancer. 9:. PubMed
  105. Cannons JL, et al. 2021. Cell Rep. 37:109804. PubMed
  106. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  107. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  108. Uhlig K, et al. 2015. J Virol. 89: 9044-9060. PubMed
  109. Israelow B, et al. 2021. Sci Immunol. 6:eabl4509. PubMed
  110. McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed
  111. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  112. Chung H, et al. 2021. Immune Netw. 21:e28. PubMed
  113. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  114. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  115. Silva M, et al. 2021. Sci Immunol. 6:eabf1152. PubMed
  116. Müller M, et al. 2021. Nat Commun. 12:7036. PubMed
  117. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  118. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  119. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  120. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
  121. Nelson SA, et al. 2022. NPJ Vaccines. 7:124. PubMed
  122. Levescot A, et al. 2021. J Clin Invest. 131:. PubMed
  123. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  124. Flommersfeld S, et al. 2021. Immunity. :. PubMed
  125. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  126. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  127. Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed
  128. Nayak RR, et al. 2021. Cell Host Microbe. 29(3):362-377.e11. PubMed
  129. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  130. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
  131. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  132. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  133. Van Braeckel-Budimir N, et al. 2018. Cell Rep. 24:3374. PubMed
  134. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  135. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  136. Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed
  137. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  138. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  139. Mendelsohn AC, et al. 2020. Am J Physiol Cell Physiol. 319:C997. PubMed
  140. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  141. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  142. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  143. Tsalavos S, et al. 2011. J Immunol. 186:6860. PubMed
  144. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  145. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  146. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  147. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  148. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  149. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  150. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  151. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  152. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  153. Qi H, et al. 2020. Cell Reports. 31(6):107621. PubMed
  154. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
  155. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  156. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  157. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  158. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  159. Pan Y, et al. 2021. NPJ Vaccines. 6:1. PubMed
  160. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  161. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  162. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
RRID
AB_493565 (BioLegend Cat. No. 104511)
AB_493564 (BioLegend Cat. No. 104512)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Other Formats

View All CD69 Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse CD69 (Maxpar® Ready) H1.2F3 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 711™ anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 700 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 650™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 785™ anti-mouse CD69 H1.2F3 FC
TotalSeq™-A0197 anti-mouse CD69 H1.2F3 PG
APC/Fire™ 750 anti-mouse CD69 H1.2F3 FC
TotalSeq™-C0197 anti-mouse CD69 H1.2F3 PG
TotalSeq™-B0197 anti-mouse CD69 H1.2F3 PG
KIRAVIA Blue 520™ anti-mouse CD69 H1.2F3 FC
Spark NIR™ 685 anti-mouse CD69 H1.2F3 FC
Biotin anti-mouse CD69 H1.2F3 FC
FITC anti-mouse CD69 H1.2F3 FC
PE anti-mouse CD69 H1.2F3 FC
PE/Cyanine5 anti-mouse CD69 H1.2F3 FC
Purified anti-mouse CD69 H1.2F3 FC,IHC-F,IP
PE/Cyanine7 anti-mouse CD69 H1.2F3 FC
APC anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 488 anti-mouse CD69 H1.2F3 FC
Alexa Fluor® 647 anti-mouse CD69 H1.2F3 FC
PerCP/Cyanine5.5 anti-mouse CD69 H1.2F3 FC
PerCP anti-mouse CD69 H1.2F3 FC
Pacific Blue™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 421™ anti-mouse CD69 H1.2F3 FC
APC/Cyanine7 anti-mouse CD69 H1.2F3 FC
Brilliant Violet 605™ anti-mouse CD69 H1.2F3 FC
Brilliant Violet 510™ anti-mouse CD69 H1.2F3 FC
Spark Red™ 718 anti-mouse CD69 H1.2F3 FC
Spark Blue™ 574 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark PLUS B550™ anti-mouse CD69 H1.2F3 FC
Spark PLUS UV395™ anti-mouse CD69 Antibody H1.2F3 FC
Spark YG™ 581 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Spark YG™ 593 anti-mouse CD69 (Flexi-Fluor™) Antibody H1.2F3 FC
Spark UV™ 387 anti-mouse CD69 (Flexi-Fluor™) H1.2F3 FC
Go To Top Version: 3    Revision Date: 04/18/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account